

Lower Respiratory Tract Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others), By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others), Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, and Competition

<https://marketpublishers.com/r/LD5EF10F403EEN.html>

Date: November 2023

Pages: 181

Price: US\$ 4,900.00 (Single User License)

ID: LD5EF10F403EEN

Abstracts

Global Lower Respiratory Tract Therapeutics Market has valued at USD 32.11 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. The global lower respiratory tract therapeutics market is a critical sector of the pharmaceutical industry, dedicated to addressing various respiratory diseases and disorders that affect millions of people worldwide. The lower respiratory tract includes the lungs and bronchial tubes, and disorders in this region can significantly impact a person's quality of life. With an aging population and the increasing prevalence of respiratory diseases, the demand for effective lower respiratory tract therapeutics is on the rise.

The global prevalence of lower respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia, and lung cancer, has been steadily increasing over the years. Factors like air pollution, smoking, and a rise in the aging population contribute to this surge in respiratory diseases. According to the World

Health Organization (WHO), more than 4 million people die annually from chronic respiratory diseases, making it one of the leading causes of death worldwide.

One notable trend in the lower respiratory tract therapeutics market is the development of targeted therapies. Advances in understanding the molecular mechanisms of respiratory diseases have paved the way for more precise and effective treatments. Targeted therapies aim to address the underlying causes of diseases, providing better outcomes and fewer side effects. Inhalation therapies, including inhalers and nebulizers, remain a preferred method for treating lower respiratory tract disorders. These devices allow patients to receive medication directly into the lungs, offering rapid relief and reduced systemic side effects. The market has seen ongoing innovation in inhalation technology, with the development of more user-friendly and efficient devices.

Key Market Drivers

Increasing Prevalence of Respiratory Disorders is Driving the Global Lower Respiratory Tract Therapeutics Market

The global healthcare landscape is witnessing a surge in the prevalence of respiratory disorders, with lower respiratory tract conditions taking center stage. These disorders, which affect the lungs and airways, are becoming increasingly common, leading to a growing demand for effective therapeutics. The global lower respiratory tract therapeutics market is experiencing remarkable growth as a result.

Respiratory disorders encompass a wide range of conditions that affect the respiratory system, which includes the lungs and airways. Among these, lower respiratory tract disorders, such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia, and bronchitis, are some of the most prevalent and debilitating. These conditions significantly impact the quality of life for millions of people worldwide, and their prevalence is on the rise. One of the key drivers behind the increasing prevalence of lower respiratory tract disorders is lifestyle changes. Factors like urbanization, pollution, exposure to tobacco smoke, and the rise in sedentary lifestyles have contributed to the escalation of respiratory problems. Additionally, aging populations are more susceptible to these conditions, as respiratory health tends to deteriorate with age.

The rise in lower respiratory tract disorders is a global phenomenon, affecting both developed and developing nations. In developing countries, indoor air pollution from cooking with solid fuels is a major contributor to respiratory illnesses, especially in rural areas. In contrast, developed countries face challenges related to air pollution, industrial

emissions, and the high prevalence of smoking. The global impact of these conditions extends beyond healthcare, affecting economies, productivity, and the overall well-being of individuals. The burden of respiratory diseases on healthcare systems is substantial, with the costs of treatment, hospitalizations, and lost productivity reaching billions of dollars annually.

As the prevalence of lower respiratory tract disorders continues to grow, there is an increasing need for effective treatments. The lower respiratory tract therapeutics market encompasses a wide range of medications, therapies, and interventions aimed at managing and alleviating the symptoms of these conditions. Bronchodilators drugs help relax the airway muscles, making it easier to breathe. They are commonly used in conditions like asthma and COPD. Reducing inflammation in the airways is crucial in managing respiratory disorders. Corticosteroids and other anti-inflammatory drugs play a vital role in this regard. For patients with severe respiratory conditions, supplemental oxygen can be a lifeline. Oxygen therapy is a significant segment of the lower respiratory tract therapeutics market.

Increasing Geriatric Population is Driving the Global Lower Respiratory Tract Therapeutics Market

The demographic structure of many countries is rapidly changing due to a combination of factors, including declining birth rates and increasing life expectancy. This demographic shift is most evident in developed nations, but it is becoming increasingly apparent in emerging economies as well. The United Nations predicts that by 2050, the global population aged 60 and above will reach 2.1 billion, nearly double the number in 2017. One of the most significant consequences of an aging population is the increased prevalence of chronic diseases. Lower respiratory tract conditions, such as chronic obstructive pulmonary disease (COPD) and pneumonia, are particularly common among older individuals. These conditions can lead to severe health complications and require ongoing medical treatment. Consequently, the demand for lower respiratory tract therapeutics is expected to rise substantially in the coming years.

The aging process is often accompanied by a decline in lung function and an increased susceptibility to respiratory illnesses. This results in a higher prevalence of conditions like COPD and pneumonia among the elderly, necessitating more significant utilization of lower respiratory tract therapeutics. Pharmaceutical companies are continually developing innovative therapies and medications for lower respiratory tract conditions. These advancements offer improved symptom management and disease control, making it more appealing for elderly patients to seek treatment. Governments and

private healthcare providers are allocating more resources to manage the healthcare needs of the elderly. This includes increased access to lower respiratory tract therapeutics, further boosting market growth. As information becomes more accessible, elderly individuals are becoming more informed about their health and treatment options. This increased awareness leads to earlier diagnosis and treatment, increasing the demand for lower respiratory tract therapeutics.

Key Market Challenges

Rising Disease Burden

One of the primary challenges facing the lower respiratory tract therapeutics market is the increasing burden of respiratory diseases. Factors such as urbanization, air pollution, smoking, and an aging population have contributed to the growing prevalence of respiratory disorders. This elevated disease burden not only strains healthcare systems but also necessitates more effective and accessible treatment options.

High Development Costs

Developing effective therapeutics for lower respiratory tract conditions is a costly and time-consuming process. Clinical trials, regulatory approvals, and research and development expenses can escalate the cost of bringing a new drug to market. Consequently, pharmaceutical companies may be deterred from investing in lower respiratory tract therapeutics, particularly for less common conditions.

Competition and Generic Drugs

The lower respiratory tract therapeutics market is highly competitive, with multiple established and emerging players vying for market share. Additionally, the expiration of patents for some leading drugs has led to the entry of generic alternatives. While this benefits patients by lowering drug costs, it poses a challenge to companies seeking to maintain profitability and invest in innovation.

Drug Resistance

The emergence of drug-resistant strains of lower respiratory tract infections, particularly in cases of pneumonia and tuberculosis, presents a significant challenge. This resistance is primarily due to overuse and misuse of antibiotics, making it harder to treat these infections effectively. Developing new antibiotics with a lower risk of resistance is

a pressing need in the market.

Access to Healthcare

Access to healthcare services, particularly in low-income and developing countries, remains a substantial challenge for patients suffering from lower respiratory tract diseases. Limited access to medical facilities, healthcare infrastructure, and affordable medications hampers the early diagnosis and treatment of these conditions, leading to higher morbidity and mortality rates.

Lack of Disease Awareness

Inadequate awareness and education about lower respiratory tract diseases among both patients and healthcare professionals is a persistent challenge. Delayed diagnosis and mismanagement can result from this lack of awareness, leading to worsened outcomes and increased healthcare costs.

Environmental Factors

Environmental factors such as air pollution, allergens, and climate change have a direct impact on the prevalence and severity of respiratory diseases. As these environmental challenges intensify, there is a growing need for comprehensive strategies that integrate environmental protection and public health.

Regulatory Hurdles

Navigating complex and evolving regulatory frameworks can be challenging for companies seeking to bring new lower respiratory tract therapeutics to market. Strict safety and efficacy requirements, as well as the need for extensive clinical trials, can prolong the time it takes for a drug to reach patients.

Key Market Trends

Technological Advancements

The field of healthcare is witnessing a transformative era, thanks to rapid technological advancements that are revolutionizing the way diseases are diagnosed, treated, and managed. One significant area benefiting from these innovations is lower respiratory tract therapeutics. Diseases affecting the lower respiratory tract, such as chronic

obstructive pulmonary disease (COPD), asthma, and pneumonia, are prevalent and often debilitating. However, the integration of cutting-edge technologies is reshaping the landscape of lower respiratory tract therapeutics.

The development of high-resolution computed tomography (HRCT) and magnetic resonance imaging (MRI) has greatly improved the diagnosis of lower respiratory tract diseases. These technologies provide detailed images of the lungs and airways, enabling early detection and precise disease staging. Advances in molecular biology and genomics have led to the discovery of specific biomarkers associated with respiratory diseases. Biomarker-based diagnostic tests allow for quicker and more accurate disease identification, leading to personalized treatment approaches. Telehealth and remote monitoring technologies have become increasingly important, especially during the COVID-19 pandemic. Patients can now consult with healthcare providers, receive real-time feedback, and access treatment plans without leaving their homes, improving disease management and reducing the risk of infection.

The advent of biologics and targeted therapies has revolutionized the treatment of respiratory diseases. Medications like monoclonal antibodies specifically target the underlying mechanisms of diseases like asthma, providing more effective and personalized treatment options. Inhalers have seen significant technological enhancements. Smart inhalers, for instance, use sensors and data analytics to monitor usage patterns and provide feedback to patients. This promotes adherence to treatment plans and better disease control. Gene therapy holds promise for treating genetic and inherited respiratory disorders. Research in this area is advancing rapidly, with the potential to provide curative treatments for diseases like cystic fibrosis.

Integrated digital health platforms and mobile applications help patients track symptoms, medications, and lung function data. These platforms provide valuable insights to both patients and healthcare providers, enabling proactive disease management. AI-powered algorithms are being used to analyze vast datasets of respiratory information, facilitating early disease detection, predicting disease progression, and optimizing treatment plans. Wearable devices and sensors allow continuous monitoring of vital signs and respiratory parameters. This real-time data can alert healthcare professionals to potential issues, enabling timely interventions.

Segmental Insights

Generic Drug Name Insights

Based on the category of Disease Type, asthma emerged as the dominant player in the global market for Lower Respiratory Tract Therapeutics in 2022. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, shortness of breath, and chest tightness. The increasing incidence of asthma has put immense pressure on healthcare systems and has spurred pharmaceutical companies to invest heavily in asthma therapeutics. Ongoing research efforts have led to the development of novel asthma therapies that offer improved effectiveness, safety, and patient convenience. Biologics and targeted therapies are reshaping the treatment landscape, allowing for more personalized approaches to asthma management. Asthma affects a substantial portion of the global population, making it a major public health concern. The sheer number of individuals with asthma creates a robust market demand for effective treatments. The shift toward patient-centric healthcare has prompted pharmaceutical companies to focus on delivering therapies that improve patients' quality of life. This approach has resulted in the development of inhalers with smart technology, user-friendly devices, and patient education programs. Environmental factors such as pollution and allergens are playing a significant role in the rise of asthma cases. As these triggers become more prevalent, the need for effective asthma therapeutics grows. Public health initiatives, advocacy groups, and healthcare organizations are working together to raise awareness about asthma and improve access to treatment. These collaborative efforts are driving investments in research and treatment options.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals have traditionally been the primary institutions for the diagnosis and treatment of severe lower respiratory tract diseases. Hospitals are equipped with state-of-the-art diagnostic facilities, such as pulmonary function testing, bronchoscopy, and imaging techniques like CT scans and X-rays. These technologies allow for accurate disease diagnosis and staging, essential for formulating effective treatment plans. Hospitals employ multidisciplinary teams of healthcare professionals, including pulmonologists, respiratory therapists, and critical care specialists, who specialize in treating lower respiratory tract diseases. This expertise is crucial in managing complex cases and tailoring treatment regimens to individual patients. Hospitals have access to the latest pharmaceuticals and therapeutic interventions for lower respiratory tract diseases. They are often involved in clinical trials, enabling patients to access promising new treatments before they become widely available. For severe cases of lower respiratory tract diseases, such as acute respiratory distress syndrome (ARDS) or advanced COPD exacerbations, hospitals offer critical care units

with ventilators and other life-saving equipment. These facilities are essential in managing acute and life-threatening respiratory conditions.

Regional Insights

North America emerged as the dominant player in the global Lower Respiratory Tract Therapeutics market in 2022, holding the largest market share in terms of value. North America boasts cutting-edge research and development infrastructure and a robust healthcare ecosystem. The region is home to numerous pharmaceutical giants and biotech companies that invest heavily in respiratory therapeutics research. Innovations in inhaler technology, drug delivery systems, and diagnostic tools have significantly improved the management of lower respiratory tract disorders. The United States and Canada house some of the world's largest pharmaceutical companies, which have dedicated resources to develop and market lower respiratory tract medications. These companies benefit from well-established regulatory pathways for drug approval, enabling them to bring new treatments to market faster. North America has a relatively high prevalence of lower respiratory tract disorders, particularly COPD and asthma. This high disease burden creates a large patient pool, making it an attractive market for pharmaceutical companies to target. Additionally, the aging population in North America is contributing to the growing demand for respiratory therapeutics.

Key Market Players

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A

Pfizer Inc.

GSK plc

Novartis AG

AstraZeneca inc.

Johnson & Johnson

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc

Report Scope:

In this report, the Global Lower Respiratory Tract Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lower Respiratory Tract Therapeutics Market, By Disease Type:

Asthma

COPD

Pneumonia

Tuberculosis

Bronchitis

Others

Lower Respiratory Tract Therapeutics Market, By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drugs

Cough Suppressants

Nasal Decongestants

Others

Lower Respiratory Tract Therapeutics Market, By Route of Administration:

Oral

Parenteral

Others

Lower Respiratory Tract Therapeutics Market, By End user:

Hospitals & Clinics

Ambulatory Care Centers

Others

Lower Respiratory Tract Therapeutics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Lower Respiratory Tract Therapeutics Market.

Available Customizations:

Global Lower Respiratory Tract Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Drug Class
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL LOWER RESPIRATORY TRACT THERAPEUTICS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others)
 - 5.2.2. By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others)

- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.5. By Region
- 5.2.6. By Company (Shares of Top 5 Market Players)
- 5.3. Market Map
 - 5.3.1. By Disease Type
 - 5.3.2. By Drug Class
 - 5.3.3. By Route of Administration
 - 5.3.4. By End User
 - 5.3.5. By Region

6. NORTH AMERICA LOWER RESPIRATORY TRACT THERAPEUTICS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Disease Type
 - 6.2.2. By Drug Class
 - 6.2.3. By Route of Administration
 - 6.2.4. By End User
 - 6.2.5. By Country
 - 6.2.5.1. United States Lower Respiratory Tract Therapeutics Market Outlook
 - 6.2.5.1.1. Market Size & Forecast
 - 6.2.5.1.1.1. By Value
 - 6.2.5.1.2. Market Share & Forecast
 - 6.2.5.1.2.1. By Disease Type
 - 6.2.5.1.2.2. By Drug Class
 - 6.2.5.1.2.3. By Route of Administration
 - 6.2.5.1.2.4. By End User
 - 6.2.5.2. Canada Lower Respiratory Tract Therapeutics Market Outlook
 - 6.2.5.2.1. Market Size & Forecast
 - 6.2.5.2.1.1. By Value
 - 6.2.5.2.2. Market Share & Forecast
 - 6.2.5.2.2.1. By Disease Type
 - 6.2.5.2.2.2. By Drug Class
 - 6.2.5.2.2.3. By Route of Administration
 - 6.2.5.2.2.4. By End User
 - 6.2.5.3. Mexico Lower Respiratory Tract Therapeutics Market Outlook

- 6.2.5.3.1. Market Size & Forecast
 - 6.2.5.3.1.1. By Value
- 6.2.5.3.2. Market Share & Forecast
 - 6.2.5.3.2.1. By Disease Type
 - 6.2.5.3.2.2. By Drug Class
 - 6.2.5.3.2.3. By Route of Administration
 - 6.2.5.3.2.4. By End User

7. EUROPE LOWER RESPIRATORY TRACT THERAPEUTICS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Disease Type
 - 7.2.2. By Drug Class
 - 7.2.3. By Route of Administration
 - 7.2.4. By End User
 - 7.2.5. By Country
 - 7.2.5.1. France Lower Respiratory Tract Therapeutics Market Outlook
 - 7.2.5.1.1. Market Size & Forecast
 - 7.2.5.1.1.1. By Value
 - 7.2.5.1.2. Market Share & Forecast
 - 7.2.5.1.2.1. By Disease Type
 - 7.2.5.1.2.2. By Drug Class
 - 7.2.5.1.2.3. By Route of Administration
 - 7.2.5.1.2.4. By End User
 - 7.2.5.2. Germany Lower Respiratory Tract Therapeutics Market Outlook
 - 7.2.5.2.1. Market Size & Forecast
 - 7.2.5.2.1.1. By Value
 - 7.2.5.2.2. Market Share & Forecast
 - 7.2.5.2.2.1. By Disease Type
 - 7.2.5.2.2.2. By Drug Class
 - 7.2.5.2.2.3. By Route of Administration
 - 7.2.5.2.2.4. By End User
 - 7.2.5.3. United Kingdom Lower Respiratory Tract Therapeutics Market Outlook
 - 7.2.5.3.1. Market Size & Forecast
 - 7.2.5.3.1.1. By Value
 - 7.2.5.3.2. Market Share & Forecast
 - 7.2.5.3.2.1. By Disease Type

- 7.2.5.3.2.2. By Drug Class
- 7.2.5.3.2.3. By Route of Administration
- 7.2.5.3.2.4. By End User
- 7.2.5.4. Italy Lower Respiratory Tract Therapeutics Market Outlook
 - 7.2.5.4.1. Market Size & Forecast
 - 7.2.5.4.1.1. By Value
 - 7.2.5.4.2. Market Share & Forecast
 - 7.2.5.4.2.1. By Disease Type
 - 7.2.5.4.2.2. By Drug Class
 - 7.2.5.4.2.3. By Route of Administration
 - 7.2.5.4.2.4. By End User
- 7.2.5.5. Spain Lower Respiratory Tract Therapeutics Market Outlook
 - 7.2.5.5.1. Market Size & Forecast
 - 7.2.5.5.1.1. By Value
 - 7.2.5.5.2. Market Share & Forecast
 - 7.2.5.5.2.1. By Disease Type
 - 7.2.5.5.2.2. By Drug Class
 - 7.2.5.5.2.3. By Route of Administration
 - 7.2.5.5.2.4. By End User

8. ASIA PACIFIC LOWER RESPIRATORY TRACT THERAPEUTICS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Disease Type
 - 8.2.2. By Drug Class
 - 8.2.3. By Route of Administration
 - 8.2.4. By End User
 - 8.2.5. By Country
 - 8.2.5.1. China Lower Respiratory Tract Therapeutics Market Outlook
 - 8.2.5.1.1. Market Size & Forecast
 - 8.2.5.1.1.1. By Value
 - 8.2.5.1.2. Market Share & Forecast
 - 8.2.5.1.2.1. By Disease Type
 - 8.2.5.1.2.2. By Drug Class
 - 8.2.5.1.2.3. By Route of Administration
 - 8.2.5.1.2.4. By End User

8.2.5.2. India Lower Respiratory Tract Therapeutics Market Outlook

8.2.5.2.1. Market Size & Forecast

8.2.5.2.1.1. By Value

8.2.5.2.2. Market Share & Forecast

8.2.5.2.2.1. By Disease Type

8.2.5.2.2.2. By Drug Class

8.2.5.2.2.3. By Route of Administration

8.2.5.2.2.4. By End User

8.2.5.3. South Korea Lower Respiratory Tract Therapeutics Market Outlook

8.2.5.3.1. Market Size & Forecast

8.2.5.3.1.1. By Value

8.2.5.3.2. Market Share & Forecast

8.2.5.3.2.1. By Disease Type

8.2.5.3.2.2. By Drug Class

8.2.5.3.2.3. By Route of Administration

8.2.5.3.2.4. By End User

8.2.5.4. Japan Lower Respiratory Tract Therapeutics Market Outlook

8.2.5.4.1. Market Size & Forecast

8.2.5.4.1.1. By Value

8.2.5.4.2. Market Share & Forecast

8.2.5.4.2.1. By Disease Type

8.2.5.4.2.2. By Drug Class

8.2.5.4.2.3. By Route of Administration

8.2.5.4.2.4. By End User

8.2.5.5. Australia Lower Respiratory Tract Therapeutics Market Outlook

8.2.5.5.1. Market Size & Forecast

8.2.5.5.1.1. By Value

8.2.5.5.2. Market Share & Forecast

8.2.5.5.2.1. By Disease Type

8.2.5.5.2.2. By Drug Class

8.2.5.5.2.3. By Route of Administration

8.2.5.5.2.4. By End User

9. SOUTH AMERICA LOWER RESPIRATORY TRACT THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Disease Type

9.2.2. By Drug Class

9.2.3. By Route of Administration

9.2.4. By End User

9.2.5. By Country

9.2.5.1. Brazil Lower Respiratory Tract Therapeutics Market Outlook

9.2.5.1.1. Market Size & Forecast

9.2.5.1.1.1. By Value

9.2.5.1.2. Market Share & Forecast

9.2.5.1.2.1. By Disease Type

9.2.5.1.2.2. By Drug Class

9.2.5.1.2.3. By Route of Administration

9.2.5.1.2.4. By End User

9.2.5.2. Argentina Lower Respiratory Tract Therapeutics Market Outlook

9.2.5.2.1. Market Size & Forecast

9.2.5.2.1.1. By Value

9.2.5.2.2. Market Share & Forecast

9.2.5.2.2.1. By Disease Type

9.2.5.2.2.2. By Drug Class

9.2.5.2.2.3. By Route of Administration

9.2.5.2.2.4. By End User

9.2.5.3. Colombia Lower Respiratory Tract Therapeutics Market Outlook

9.2.5.3.1. Market Size & Forecast

9.2.5.3.1.1. By Value

9.2.5.3.2. Market Share & Forecast

9.2.5.3.2.1. By Disease Type

9.2.5.3.2.2. By Drug Class

9.2.5.3.2.3. By Route of Administration

9.2.5.3.2.4. By End User

10. MIDDLE EAST & AFRICA LOWER RESPIRATORY TRACT THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Disease Type

10.2.2. By Drug Class

10.2.3. By Route of Administration

10.2.4. By End User

10.2.5. By Country

10.2.5.1. South Africa Lower Respiratory Tract Therapeutics Market Outlook

10.2.5.1.1. Market Size & Forecast

10.2.5.1.1.1. By Value

10.2.5.1.2. Market Share & Forecast

10.2.5.1.2.1. By Disease Type

10.2.5.1.2.2. By Drug Class

10.2.5.1.2.3. By Route of Administration

10.2.5.1.2.4. By End User

10.2.5.2. Saudi Arabia Lower Respiratory Tract Therapeutics Market Outlook

10.2.5.2.1. Market Size & Forecast

10.2.5.2.1.1. By Value

10.2.5.2.2. Market Share & Forecast

10.2.5.2.2.1. By Disease Type

10.2.5.2.2.2. By Drug Class

10.2.5.2.2.3. By Route of Administration

10.2.5.2.2.4. By End User

10.2.5.3. UAE Lower Respiratory Tract Therapeutics Market Outlook

10.2.5.3.1. Market Size & Forecast

10.2.5.3.1.1. By Value

10.2.5.3.2. Market Share & Forecast

10.2.5.3.2.1. By Disease Type

10.2.5.3.2.2. By Drug Class

10.2.5.3.2.3. By Route of Administration

10.2.5.3.2.4. By End User

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Technology Launches

13. COMPETITIVE LANDSCAPE

13.1. F. Hoffmann-La Roche Ltd.

13.1.1. Business Overview

13.1.2. Patient Offerings

13.1.3. Recent Developments

13.1.4. Key Personnel

13.1.5. SWOT Analysis

13.2. Teva Pharmaceutical Industries Ltd.

13.3. Sanofi S.A

13.4. Pfizer Inc.

13.5. GSK plc

13.6. Novartis AG

13.7. AstraZeneca

13.8. Johnson & Johnson

13.9. Sun Pharmaceutical Industries Ltd.

13.10. Merck & Co., Inc

14. STRATEGIC RECOMMENDATIONS

About us & Disclaimer

I would like to order

Product name: Lower Respiratory Tract Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others), By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others), Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, and Competition

Product link: <https://marketpublishers.com/r/LD5EF10F403EEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LD5EF10F403EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970